The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma
Authors:
- Zhi-Hong JianZJZhi-Hong Jian
- Jing-Yang HuangJHJing-Yang Huang
- Frank Cheau-Feng LinFrank Cheau-Feng Lin
- Oswald Ndi NforONOswald Ndi Nfor
- Kai-Ming JhangKJKai-Ming Jhang
- Wen-Yuan KuWKWen-Yuan Ku
- Chien-Chang HoCHChien-Chang Ho
- Chia-Chi LungCLChia-Chi Lung
- Hui-Hsien PanHPHui-Hsien Pan
- Yu-Chiu LiangYLYu-Chiu Liang
- Ming-Fang WuMWMing-Fang Wu
- Yung-Po LiawYLYung-Po Liaw
Open Access
- 3 December 2015
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 15 (1) , 154
Abstract
Asthma and COPD (chronic obstructive pulmonary disease) lead to persistent airway inflammation and are associated with lung cancer. The objective of the study was to assess the relationship between inhaled (ICS) and oral corticosteroid (OCS) use, and risk of lung squamous cell carcinoma (SqCC). This study was a nested case–control study. Patients with newly diagnosed asthma or COPD between 2003 and 2010 were identified from the National Health Insurance Database. Cases were defined as patients diagnosed with SqCC after enrollment. For each case, four control individuals who were randomly matched for sex and age and date diagnosis of asthma or COPD were selected. From the 1,672,455 eligible participants, 793 patients with SqCC were matched with 3,172 controls. The odds ratios (ORs) of SqCC in men who received high and low-dose ICS were 2.18 (95 %CI, 1.56–3.04) and 1.77 (1.22–2.57), respectively. Similarly, the ORs were 1.46 (95 %CI, 1.16–1.84) and 1.55 (95 %CI, 1.22–1.98) for men who were placed on low and high dose OCS. However, there was no significant association between cumulative ICS and/or OCS and risk of SqCC in women. Recent dose increase in corticosteriod was significantly associated with risk of SqCC. Specifically, among men, the ORs for SqCC were 8.08 (95 %CI, 3.22–20.30) for high-dose ICS + OCS, 4.49 (95 % CI, 2.05–9.85) for high-dose ICS, and 3.54 (95 % CI, 2.50–5.01) for high-dose OCS treatments, respectively. The OR for SqCC in women who received high-dose OCS was 6.72 (95 %CI, 2.69–16.81). Corticosteroid use did not decrease SqCC in patients with asthma or COPD. Recent dose increase in corticosteroids was associated with SqCC.Keywords
This publication has 39 references indexed in Scilit:
- Comparison of expected health impacts for major cancers: Integration of incidence rate and loss of quality-adjusted life expectancyCancer Epidemiology, 2015
- The Role of Corticosteroids in Chronic Obstructive Pulmonary DiseaseSeminars in Respiratory and Critical Care Medicine, 2005
- Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressionsOncogene, 2004
- Is airway remodeling clinically relevant in asthma?The American Journal of Medicine, 2003
- Gender differences in pulmonary disease.2003
- The Potential Contributions of Chronic Inflammation to Lung CarcinogenesisClinical Lung Cancer, 2003
- Low Lung Function and Incident Lung Cancer in the United StatesArchives of internal medicine (1960), 2003
- Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program.2003
- The Heterogeneity in Risk Factors of Lung Cancer and the Difference of Histologic Distribution between Genders in TaiwanCancer Causes & Control, 2001
- Prednisolone Treatment in Asthma. Reduction in the Numbers of Eosinophils, T Cells, Tryptase-Only Positive Mast Cells, and Modulation of IL-4, IL-5, and Interferon-Gamma Cytokine Gene Expression Within the Bronchial MucosaAmerican Journal of Respiratory and Critical Care Medicine, 1996